On-line version ISSN 1414-431X
Braz J Med Biol Res vol.40 no.7 Ribeirão Preto July 2007 Epub June 06, 2007
Duodenal gastric metaplasia and Helicobacter pylori infection in patients with diffuse nodular duodenitis
1Department of Gastroenterology, 2Department of Pathology, Renji Hospital, Shanghai Institute of Digestive Diseases, Medical College of Shanghai Jiaotong University, Shanghai, China
Whether the regression of gastric metaplasia in the duodenum can be achieved after eradication of Helicobacter pylori is not clear. The aim of the present study was to investigate the relationship between H. pylori infection and gastric metaplasia in patients with endoscopic diffuse nodular duodenitis. Eighty-six patients with endoscopically confirmed nodular duodenitis and 40 control patients with normal duodenal appearance were investigated. The H. pylori-positive patients with duodenitis received anti-H. pylori triple therapy (20 mg omeprazole plus 250 mg clarithromycin and 400 mg metronidazole, all twice daily) for one week. A control endoscopy was performed 6 months after H. pylori treatment. The H. pylori-negative patients with duodenitis received 20 mg omeprazole once daily for 6 months and a control endoscopy was performed 2 weeks after treatment. The prevalence of H. pylori infection was 58.1%, and the prevalence of gastric metaplasia was 57.0%. Seventy-six patients underwent endoscopy again. No influence on the endoscopic appearance of nodular duodenitis was found after eradication of H. pylori or acid suppression therapy. However, gastric metaplasia significantly decreased and complete regression was achieved in 15/28 patients (53.6%) 6 months after eradication of H. pylori, accompanied by significant improvement of other histological alterations. Only mild chronic inflammation, but not gastric metaplasia, was found in the control group, none with H. pylori infection in the duodenal bulb. Therefore, H. pylori infection is related to the extent of gastric metaplasia in the duodenum, but not to the presence of diffuse nodular duodenitis.
Key words: Nodular duodenitis, Helicobacter pylori, Gastric metaplasia
Helicobacter pylori infection is a major cause of many gastroduodenal diseases, especially chronic gastritis, duodenal ulcer, and duodenitis. Since the colonization of the duodenum by H. pylori occurs only in regions of gastric metaplasia (GM), the development of duodenal GM is critically important in the pathogenesis of duodenal ulcer and duodenitis. In previous studies, the prevalence of GM was 72 to 90% in patients with duodenal ulcer, 40 to 95% in patients with duodenitis, and 0 to 33% in patients with normal endoscopic duodenal appearance (1,2).
GM is generally believed to occur as a non-specific response to acid/peptic damage. It has been speculated that H. pylori infection induces a high level of acid burden in the duodenum by increasing gastrin secretion, which may influence the development of GM. It has been shown that the amount of H. pylori in the duodenal bulb may be related to the extent of GM (3). Theoretically, regression of GM may be induced by eradication of H. pylori or acid-suppression therapy. However, published results are conflicting and few studies have focused on the relationship between H. pylori infection and GM in the pathogenesis of duodenitis (4-11).
Clinically, we observed quite a few patients with endoscopic diffuse nodularity, which is independent of duodenal ulceration, in the duodenal bulb. This alteration may be a special type of chronic duodenitis. The purpose of the present prospective study was to investigate the association between H. pylori infection and GM in patients with diffuse nodular duodenitis.
Between January 2002 and June 2005, 86 patients with endoscopically confirmed diffuse nodular duodenitis (Figure 1) were enrolled, including 50 patients (22 males; median age 49.0 years, range 23-75 years) with H. pylori infection and 36 patients (13 males; median age 52.6 years, range 22-76 years) without H. pylori infection. Forty patients (14 males; median age 51.6 years, range 20-78 years) with normal appearance of the duodenum were used as controls.
Patients were excluded who had 1) evidence of gastroduodenal malignancies, gastric ulcer, duodenal ulcer, or scar on gastroscopy; 2) liver, biliary, or pancreatic diseases on ultrasound examination; 3) received proton pump inhibitors (PPIs, such as omeprazole, lansoprazole, rabeprazole, and pantoprazole, etc.), bismuth, antibiotics, aspirin, or other non-steroidal anti-inflammatory drugs (NSAID) in the preceding 2 weeks; 4) Zollinger-Ellison syndrome or Crohn's disease involving the duodenum; 5) previous upper gastrointestinal surgery; 6) pregnancy, or 7) renal insufficiency or other severe concomitant illnesses. This study was approved by the Medicine Ethics Committee of Shanghai Renji Hospital and signed informed consent was obtained from all patients.
[View larger version of this image (25 K JPG file)]
Patients with endoscopically confirmed diffuse nodular duodenitis were treated with anti-H. pylori triple therapy consisting of 20 mg omeprazole twice daily, 250 mg clarithromycin twice daily, and 400 mg metronidazole twice daily for one week when H. pylori infection was diagnosed either in the duodenal bulb or in the gastric antrum. A control endoscopy was performed 6 months after the anti-H. pylori treatment. The H. pylori-negative (both in the duodenal bulb and in the gastric antrum) patients with diffuse nodular duodenitis received 20 mg omeprazole once daily for 6 months and a control endoscopy was performed 2 weeks after treatment. During the follow-up period after eradication treatment, intermittent short courses of hydrotalcite or sucralfate were prescribed to avoid symptoms and PPIs were avoided when possible.
Endoscopy and biopsy sampling
Endoscopic findings of duodenal morphology were defined according to the criteria of endoscopic duodenitis described by the Sydney classification (12), including the subjective assessment of severity as mild, moderate or severe. During each endoscopic examination, three antral biopsies were taken from the lesser and the greater curvature within 2-3 cm from the pylorus, and two duodenal biopsies were taken from the diffuse nodular lesion in the duodenal bulb. Among these biopsies, one antral specimen was used to detect H. pylori by the rapid urease test, and the others were used for histological assessment.
The biopsy specimens for histological examination were fixed in 10% formalin, embedded in paraffin on the oriented edge, and cut into 4-µm thick sequential sections. The tissue sections were then stained with hematoxylin and eosin for histological examination, with Alcian blue periodic acid-Schiff (AB/PAS) for identifying and assessing the extent of GM, and with Giemsa for H. pylori assessment.
The slides were evaluated by an experienced pathologist who was blind to clinical, endoscopic and other tests for H. pylori. Gastric antral and duodenal biopsy specimens were assessed according to the updated Sydney System (12). In each duodenal biopsy specimen, the infiltration of the duodenal mucosa by mononuclear cells (chronic inflammation) and polymorphonuclear leukocytes (neutrophilic activity) was graded as follows: 0, none; 1, mild; 2, moderate; 3, severe. GM was defined by the presence of surface epithelial cells containing PAS-positive neutral mucin in the duodenal bulb. The extent of gastric type epithelium in duodenal biopsy specimens was arbitrarily graded on a scale of 0-3 as follows: grade 0, no GM observed; grade 1, GM involving a few villi; grade 2, GM involving several villi, and grade 3, GM involving almost all villi (12). The lymphoid follicles were considered to be positive when aggregates of lymphocytes with a germinal center (secondary lymphoid follicles) or accumulations of lymphocytes and plasma cells without a germinal center (primary lymphoid aggregates) were observed. Villus atrophy was defined as flattening or widening of villi. H. pylori infection was diagnosed when the rapid urease test, hematoxylin and eosin stain, and Giemsa stain were all positive.
Data are reported as means ± SD. Differences were evaluated by the Fisher exact test, t-test, or Wilcoxon signed rank test. P values of <0.05 were considered significant.
Helicobacter pylori status
Fifty patients (50/86, 58.1%) were H. pylori positive. Among the 76 patients who completed the study, 48 were H. pylori positive. After eradication treatment, 9 patients were still H. pylori positive.
Pre-treatment endoscopic appearance and histological findings
No common pathogenic factors, such as renal transplantation or duodenal parasitic infestation, were present in patients with nodular duodenitis. There was no significant difference in the severity of endoscopic nodular duodenitis between the H. pylori-positive and -negative groups (P = 0.144, Table 1).
GM was detected in 49 of the 86 patients (57.0%). The prevalence of GM, villus atrophy, goblet cell reduction, and lymphoid follicles was significantly higher in patients with H. pylori infection than in patients without H. pylori infection (P < 0.05 for all). The extent of GM was also greater in H. pylori-positive patients than that in H. pylori-negative patients (P = 0.032, Table 2). Furthermore, different degrees of chronic duodenal inflammation (average score, 3.4 ± 1.3) and neutrophilic activity (average score, 2.3 ± 1.9) were found in most of the patients with nodular duodenitis.
Only mild duodenal chronic inflammation (average score 0.8 ± 1.0) was found in 30 of 40 control patients with normal appearance of the duodenum. The values were significantly lower than those in H. pylori-positive or -negative patients in the treatment group (both P < 0.0001). No other histological alterations, including GM, were found in this group.
[View larger version of this image (42 K JPG file)]
[View larger version of this image (48 K JPG file)]
Post-treatment endoscopic appearance and histological changes
Seventy-six patients completed the study, including 48 patients with H. pylori eradication treatment (successful in 39) and 28 patients with PPI treatment. Neither the successful eradication treatment nor PPI treatment could improve the endoscopic appearance of nodular duodenitis (both P > 0.05, Table 1).
Six months after successful eradication of H. pylori, both the values of chronic inflammation and neutrophilic activity were significantly decreased (2.2 ± 1.2 vs 4.0 ± 1.5, P < 0.0001, and 0.1 ± 0.3 vs 3.8 ± 1.5, P < 0.0001, respectively). Furthermore, the extent of duodenal GM was significantly reduced (P = 0.0001, Table 2), and regression of histological alterations was achieved in most or all patients (Table 3).
However, no significant change in histological findings, including GM, was found in H. pylori-negative patients on PPI treatment or in patients with persistent H. pylori infection after eradication treatment (Table 3).
[View larger version of this image (44 K JPG file)]
An association between GM, H. pylori infection and duodenitis has been reported (13-15). GM of the duodenum is characterized by the metaplastic replacement of the normal duodenal epithelial cells with those displaying a phenotype similar to that of mucus-secreting cells of the gastric mucosa. It resembles gastric foveolar epithelium in many respects, including H. pylori colonization (16,17). It has been suggested that the presence of GM may create a suitable environment for H. pylori colonization in the duodenum, resulting in chronic duodenitis (13,14,17,18). The development of metaplastic tissue is a necessary prerequisite for H. pylori colonization because the bacterium may survive in the gastric mucosa but it cannot grow on normal duodenal epithelium (13,16,18). When spread to the duodenal mucosa, H. pylori is believed to exert a cytotoxic effect on mucosal cells. The inflammatory injury to duodenal mucosa by H. pylori may eventually lead to the development of further GM (13,14,19). H. pylori infection was confirmed to be one of the independent risk factors of GM (20), and an inductive role of H. pylori in the development of GM was suggested recently (21).
However, there are conflicting reports concerning the relationship between the extent of GM and H. pylori infection. It has been reported that neither the prevalence nor the extent of GM was affected by H. pylori status (5,6,9,22). In contrast, some studies found such a relationship between the extent of GM in the duodenum and the amount of H. pylori in the gastric antrum or in the duodenal bulb (3,4,13,17). Our study showed that both the presence and the extent of GM in nodular duodenitis are related to the presence of H. pylori infection.
There are also conflicting reports as to whether the extent of GM decreases after eradication of H. pylori. Some studies have shown no decrease in the extent of GM after eradication of H. pylori (5-7,9-11), whereas a significant reduction in the extent of GM was demonstrated in others (4,8). In agreement with the latter reports, the results of the present study showed that the extent of GM significantly decreased and complete regression occurred in more than half (15/28) the patients 6 months after eradication of H. pylori. In addition, the patients with successful eradication of H. pylori show a significantly higher prevalence of GM regression than those with no eradication. These findings further confirm the important contributory role of H. pylori infection in the development and persistence of GM.
In addition to H. pylori infection, it was speculated that the presence of duodenal GM is most likely caused by duodenal injury or high acidity (14,15), and is considered to be a protective mechanism to excess acid (23). But long-term acid inhibition treatment with H2-receptor antagonists could not decrease the extent of GM (5). It was shown in another study that acid suppression alone produced a 43% reduction in GM, similar to the effect of H. pylori eradication. The authors concluded that the extent of GM was partly due to H. pylori and partly to acid (4). In the present study, only 20% regression in GM could be achieved with long-term acid inhibition treatment alone in patients without H. pylori infection. However, the results of PPI treatment should be interpreted with caution because the acidity levels were not evaluated. This aspect deserves further investigation.
Diffuse nodular duodenitis is a special type of chronic duodenitis. Up to now, we know little about its pathogenesis. It was speculated that the appearance of endoscopic findings of duodenitis may result from H. pylori infection or from an acid-pepsin attack and is usually accompanied with some histopathologic abnormalities, including GM (17). However, few studies had focused on the association between the appearance of duodenitis and H. pylori infection. It has been reported that no significant difference exists in the severity of endoscopic duodenitis between H. pylori-positive and -negative patients, and successful eradication of H. pylori did not lead to any change in endoscopic appearance (9). In agreement with this finding, we found that neither the eradication of H. pylori nor the acid suppression treatment could change the appearance of endoscopic nodular duodenitis in a significant manner.
In conclusion, the present results suggest that H. pylori infection is related to the extent of GM in the duodenum, but not to the presence of diffuse nodular duodenitis.
1. Heikkinen M, Pikkarainen P, Vornanen M, Hollmen S, Julkunen R. Prevalence of gastric metaplasia in the duodenal bulb is low in Helicobacter pylori positive non-ulcer dyspepsia patients. Dig Liver Dis 2001; 33: 459-463. [ Links ]
2. Chen XY, Shi Y, Peng YS, Ma YZ, Xiao SD. Relationship between Helicobacter pylori infection and gastric metaplasia in the mucosa of duodenal bulb. Chin J Dig 2004; 9: 519-522. [ Links ]
3. Futami H, Takashima M, Furuta T, Hanai H, Kaneko E. Relationship between Helicobacter pylori infection and gastric metaplasia in the duodenal bulb in the pathogenesis of duodenal ulcer. J Gastroenterol Hepatol 1999; 14: 114-119. [ Links ]
4. Khulusi S, Badve S, Patel P, Lloyd R, Marrero JM, Finlayson C, et al. Pathogenesis of gastric metaplasia of the human duodenum: role of Helicobacter pylori, gastric acid, and ulceration. Gastroenterology 1996; 110: 452-458. [ Links ]
5. Noach LA, Rolf TM, Bosma NB, Schwartz MP, Oosting J, Rauws EA, et al. Gastric metaplasia and Helicobacter pylori infection. Gut 1993; 34: 1510-1514. [ Links ]
6. Harris AW, Gummett PA, Walker MM, Misiewicz JJ, Baron JH. Relation between gastric acid output, Helicobacter pylori, and gastric metaplasia in the duodenal bulb. Gut 1996; 39: 513-520. [ Links ]
7. Savarino V, Mela GS, Zentilin P, Mele MR, Bisso G, Pivari M, et al. Effect of Helicobacter pylori eradication on 24-hour gastric pH and duodenal gastric metaplasia. Dig Dis Sci 2000; 45: 1315-1321. [ Links ]
8. Ciancio G, Nuti M, Orsini B, Iovi F, Ortolani M, Palomba A, et al. Regression of duodenal gastric metaplasia in Helicobacter pylori positive patients with duodenal ulcer disease. Dig Liver Dis 2002; 34: 16-21. [ Links ]
9. Urakami Y, Sano T. Endoscopic duodenitis, gastric metaplasia and Helicobacter pylori. J Gastroenterol Hepatol 2001; 16: 513-518. [ Links ]
10. Urakami Y, Sano T. Long-term follow-up of gastric metaplasia after eradication of Helicobacter pylori. J Med Invest 2003; 50: 48-54. [ Links ]
11. Bago J, Strinic D, Halle ZB, Jandric D, Tomic M, Bilic A, et al. Effect of Helicobacter pylori eradication on extent of duodenal gastric metaplasia and grade of gastritis. Coll Antropol 2002; 26: 557-563. [ Links ]
12. Tytgat GN. The Sydney System: endoscopic division. Endoscopic appearances in gastritis/duodenitis. J Gastroenterol Hepatol 1991; 6: 223-234. [ Links ]
13. Madsen JE, Vetvik K, Aase S. Helicobacter -associated duodenitis and gastric metaplasia in duodenal ulcer patients. APMIS 1991; 99: 997-1000. [ Links ]
14. Satoh K, Kimura K, Yoshida Y, Kasano T, Kihira K, Taniguchi Y. Relationship between Helicobacter pylori colonization and acute inflammation of the duodenal mucosa. Am J Gastroenterol 1993; 88: 360-363. [ Links ]
15. Fitzgibbons PL, Dooley CP, Cohen H, Appleman MD. Prevalence of gastric metaplasia, inflammation, and Campylobacter pylori in the duodenum of members of a normal population. Am J Clin Pathol 1988; 90: 711-714. [ Links ]
16. Carrick J, Lee A, Hazell S, Ralston M, Daskalopoulos G. Campylobacter pylori, duodenal ulcer, and gastric metaplasia: possible role of functional heterotopic tissue in ulcerogenesis. Gut 1989; 30: 790-797. [ Links ]
17. Wyatt JI, Rathbone BJ, Sobala GM, Shallcross T, Heatley RV, Axon AT, et al. Gastric epithelium in the duodenum: its association with Helicobacter pylori and inflammation. J Clin Pathol 1990; 43: 981-986. [ Links ]
18. Johan G, Offerhaus A, Molyvas EN, Hoedemaeker PJ. Helicobacter pylori infection of gastric mucin cell metaplasia: the duodenum revisited. J Pathol 1990; 162: 239-243. [ Links ]
19. Walker MM, Dixon MF. Gastric metaplasia: its role in duodenal ulceration. Aliment Pharmacol Ther 1996; 10 (Suppl 1): 119-128. [ Links ]
20. Voutilainen M, Juhola M, Farkkila M, Sipponen P. Gastric metaplasia and chronic inflammation at the duodenal bulb mucosa. Dig Liver Dis 2003; 35: 94-98. [ Links ]
21. Van De Bovenkamp JH, Korteland-Van Male AM, Buller HA, Einerhand AW, Dekker J. Metaplasia of the duodenum shows a Helicobacter pylori-correlated differentiation into gastric-type protein expression. Hum Pathol 2003; 34: 156-165. [ Links ]
22. Suriani R, Venturini I, Actis GC, Rocca G, Rizzetto M, Cerutti E, et al. Effect of Helicobacter pylori eradication on bulbitis and duodenal gastric metaplasia. Hepatogastroenterology 2004; 51: 176-180. [ Links ]
23. James AH. Gastric epithelium in the duodenum. Gut 1964; 5: 285-294. [ Links ]
Address for correspondence: X.B. Li, Shandong Zhong Road, 145, 200001, Shanghai, China. Fax: +86-021-56338496. E-mail: firstname.lastname@example.org
Research supported by Shanghai leading academic discipline project (No. Y0205). Received April 28, 2006. Accepted April 26, 2007.